Haleon plc (NYSE:HLN) Position Increased by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV increased its position in Haleon plc (NYSE:HLN) by 56.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 266,881 shares of the company’s stock after purchasing an additional 96,574 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Haleon were worth $2,546,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Sierra Ocean LLC acquired a new position in Haleon in the 4th quarter valued at approximately $26,000. Versant Capital Management Inc boosted its holdings in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after purchasing an additional 3,348 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Haleon in the 4th quarter valued at approximately $35,000. FIL Ltd boosted its position in Haleon by 45.7% during the fourth quarter. FIL Ltd now owns 4,049 shares of the company’s stock worth $39,000 after purchasing an additional 1,270 shares during the period. Finally, Spire Wealth Management bought a new stake in shares of Haleon during the 4th quarter worth $39,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on HLN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Finally, Morgan Stanley downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Haleon has an average rating of “Hold” and a consensus target price of $10.95.

Haleon Stock Up 0.3 %

NYSE HLN opened at $10.67 on Wednesday. The stock has a fifty day moving average of $10.19 and a 200-day moving average of $9.82. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $48.12 billion, a P/E ratio of 31.37, a price-to-earnings-growth ratio of 2.82 and a beta of 0.24. Haleon plc has a 52 week low of $8.12 and a 52 week high of $10.85.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, equities research analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is a positive change from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s dividend payout ratio (DPR) is 58.97%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.